Opioid substitution treatment in France: 2023 report
In a glimpse, OFDT, 1 p.
March 2023
The aim of this report, produced by the French Monitoring Centre for Drugs and Drug Addiction (OFDT), is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.
The first part of the report describes the sociodemographic breakdown of people receiving payment for opioid substitution medications (OSM) in primary care in 2020, as well as their treatment methods. These data come from the simplified generalist sample of recipients (EGBS) of the French National Health Insurance Fund. They are supplemented by the data on prescriptions and supply of OSMs in CSAPA specialised drug treatment centres (2019), data on the prescriptions and supply of OSMs in prisons (2020), and data of sales of OSMs in France (2022). The second part of the report presents data on misuse, deaths related to OSM drugs, and the sale of naloxone.
Download In a glimpse, opioid substitution treatment in France: 2023 report (251 Ko, 1p.)
Drugs in Europe
2023 EMCDDA European Drug Report
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions. This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.
